cyrilzakka/clinical-trials huggingface dataset:
An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)

The project was undertaking by Qilu Hospital of Shandong University and other 7 well-known hospitals in China. In order to report the efficacy and safety of different dose dexamethasone in treating the immune thrombocytopenia (ITP).

The investigators are undertaking a parallel group, multicentre, randomised controlled trial of 60 adults with ITP from 7 medical centers in China. Part of the participants are randomly selected to receive dexamethasone (given at a dose of 40mg per day for 4 consecutive days) ,the others are selected to receive dexamethasone(given at a dose of 20 mg daily for 4 days).

Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study. In order to report the efficacy and safety of different dose dexamethasone for the treatment of adults with immune thrombocytopenia (ITP).

Eligibility Criteria:
Inclusion Criteria:

1. Meet the diagnostic criteria for immune thrombocytopenia
2. Untreated hospitalized patients, may be male or female, between the ages of 18 \~ 75 years
3. To show a platelet count \<30 \* 10\^9/L, and with bleeding manifestations
4. Willing and able to sign written informed consent

Exclusion Criteria:

1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit
2. Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit
3. Received high-dose steroids or IVIG in the 3 weeks prior to the start of the study
4. Current HIV infection or hepatitis B virus or hepatitis C virus infections
5. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)
6. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period
7. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test
8. Patients who are deemed unsuitable for the study by the investigator
Efficacy of Cognitive Training in Subjective Memory Impairment

This study evaluates the efficacy of cognitive training in subjects with subjective memory impairment. The first group will receive cognitive training and lifestyle modification in combination, the second group will receive only lifestyle modification, and the third group will receive no intervention.

Subjective memory impairment is currently thought to be a risky state of progression to Alzheimer's disease. This study aims to confirm whether cognitive training in subjective memory impairment would show improvement in the subjective and objective cognition. We include subjects with normal cognition but complained subjective feeling of memory decline and conduct cognitive training programs combined with lifestyle modifications for 3 months. We evaluate the neuropsychological tests and questionnaires about subjective improvement after 3 months of interventions.

Eligibility Criteria:
Inclusion Criteria:

* Subjects who showed normal range (above 16percentile of norm) in all domains of detailed neuropsychological tests battery named Seoul Neuropsychological Screening Battery (SNSB)
* Clinical dementia rating (CDR) score of 0
* Subjects with at least 3 years of formal education

Exclusion Criteria:

* Subjects with mild cognitive impairment or dementia
* Subjects who was diagnosed as any neurological disorders such as epilepsy, stroke, hemorrhage, hydrocephalus, Parkinson's disease or brain tumor
* Subjects with uncontrolled severe medical conditions according to investigator's opinion
Bag Valve Mask vs Non-rebreather at Flush Rate

Healthy volunteers will participate in a crossover trial comparing preoxygenation with a non-rebreather mask to a bag-valve mask (with and without a simulated mask leak) at the flush rate of oxygen (fully opening standard oxygen flowmeter).


Eligibility Criteria:
Inclusion Criteria:

* Age \>17

Exclusion Criteria:

* Pregnant
* Any facial hair more than stubble that might impede a mask seal
Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function and Blood Markers of Cardiovascular Risk

The purpose of this study is to evaluate the effects of freeze dried strawberry powder on LDL cholesterol, central and peripheral blood pressure, indices of arterial stiffness, and other lipid and lipoprotein concentrations. The investigators hypothesize that the bioactive compounds in freeze dried strawberry powder may elicit beneficial effects on LDL cholesterol, as well as blood pressure and arterial health.

The proposed study design is a 3-period randomized crossover dose-response study to evaluate the effect of freeze dried strawberry powder supplementation on LDL-C and vascular health. Research participants will be overweight or obese (BMI 25-39 kg/m\^2) but otherwise healthy adults with moderately elevated LDL-C (\>116 mg/dL or \>3.0mmol/L), blood pressure \<160/100 mmHg, total cholesterol below 273 mg/dL for men and below 284 mg/dL for women, and triglycerides below 350 mg/dL. Subjects will be randomly assigned to three supplementation periods: 1) low dose freeze dried strawberry powder (13 g/d); 2) high dose freeze dried strawberry powder (40 g/d); and 3) a placebo powder. Each powder will be provided for 4-6 weeks, separated by a 2-week washout period between treatment periods. Baseline and endpoint testing will include blood collection and vascular testing.

Eligibility Criteria:
Inclusion Criteria:

1. Men and women 35-65 years of age
2. BMI ≥ 25 and ≤ 39 kg/m\^2
3. LDL-C \> 116 mg/dL
4. Total Cholesterol below 273 mg/dL for men and below 284 mg/dL for women
5. Triglycerides below 350 mg/d
6. Non-smokers
7. Blood pressure \< 160/100 mmHg

Exclusion Criteria:

1. History of acute or chronic inflammatory conditions or heart disease, kidney disease, liver disease, autoimmune disorders, or thyroid disease (unless controlled by medication and blood results within the previous 6 months are provided)
2. History of diabetes mellitus (and/or a fasting glucose \> 126 mg/dL at screening)
3. Stage II hypertension (blood pressure ≥ 160/100 mmHg)
4. Lactation, pregnancy, or desire to become pregnant during the study
5. Unwillingness to discontinue nutritional supplements, herbs, or vitamins, unless approved by investigator
6. Use of medications/supplements for elevated lipids, blood pressure, or glucose
7. Chronic use of non-steroidal anti-inflammatory or immunosuppressant medication
8. Conditions requiring the use of steroids
9. Unwillingness to refrain from blood donation prior to and during the study
10. Any medical condition or abnormal laboratory value that is judged clinically significant by an investigator
11. Allergy or sensitivity to strawberries or any ingredient in the study powders
Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma

The purpose of this study is to determine whether antiepileptic drug oxcarbazepine is effective in the treatment of chronic asthma.

Effective therapy of asthma still remains quite serious problem. According GINA definition, asthma is an inflammatory disorder. Consequently, modern pharmacotherapy of asthma provides wide use of anti-inflammatory drugs. But asthma also is a paroxysmal disorder: many specialists and even some guidelines underline paroxysmal clinical picture of asthma. Besides this, according to some authors, neurogenic inflammation may play important role in asthma mechanism. But some other neurogenic inflammatory paroxysmal disorders exist, and they are migraine and trigeminal neuralgia. Some antiepileptic drugs, like carbamazepine and valproate, are very effective in therapy of migraine and trigeminal neuralgia - more than in 80% of cases. If bronchial asthma also is paroxysmal inflammatory disease, like migraine and trigeminal neuralgia, it is possible that some antiepileptic drugs also are very effective in asthma therapy.

We performed a double-blind, placebo-controlled 3-month trial for evaluation of oxcarbazepine efficacy in therapy of bronchial asthma. Oxcarbazepine is antiepileptic drug of new generation, produced by Novartis, and it is more effective and safe derivative of well-known antiepileptic drug carbamazepine.

Comparison: Patients received investigational drug in addition to their usual routine antiasthmatic treatment, compared to patients received placebo in addition to their usual routine antiasthmatic treatment.

Eligibility Criteria:
Inclusion Criteria:

* Bronchial asthma has been known at least for 1 year
* Absence of long-term remissions of asthma (lasting more than 1 month)
* Poorly controlled asthma, due to various reasons
* Non-smokers

Exclusion Criteria:

* Presence of concomitant severe diseases
* Allergy or adverse reactions to carbamazepine or oxcarbazepine
* Abnormal baseline haematology, blood chemistry or urinalysis
* Current use of long-acting beta-agonists
* Age younger than 16 years old
* Long-term history of smoking
* Pregnancy or lactating
New Biomarkers of Neurological Outcome After a Sudden Cardiac Death

The aim of the project is to establish the value of circulating microparticles as a new biomarker for neurological prognosis of patients recovered from sudden cardiac death who remain comatose.

This is a pilot study. Analytical, observational, longitudinal, retrospective and prospective, non-randomized. Patients recovered from sudden cardiac death of ischemic cause and remain comatose will be included in the protocol if they fit the pre-specified inclusion criteria. Biological samples will be collected (at admission, at 24 and 72 hours) and stored in the Biobank of Hospital de la Santa Creu i Sant Pau for further analysis. In addition demographic, clinical and analytical variables will be collected. At the end of the recruitment period, we will analyse the concentrations of circulating microparticles according to ICCC-IIBSantPau methodology in the samples obtained. The primary outcome variable will be the neurological status at Coronary Care Unit discharge and at 6 months. The objective of the study will evaluate the relationship between the neurological status and the blood concentrations of circulating microparticles.

Eligibility Criteria:
Inclusion Criteria:

* Over 18 years old.
* Patients recovered from a sudden cardiac death (in-hospital and out-of-hospital) with return of spontaneous circulation (ROSC) (defined as systolic blood pressure \> 60 mmHg or palpable pulse for \> 5 minutes) who remain unconsciousness (defined as a score on the Glasgow Coma Scale \<8 ) for \> 5-10 minutes after ROSC.
* Treated with hypothermia as recommended by the European guidelines for resuscitation ( 2010)..

Exclusion Criteria:

* Non-cardiac sudden death.
* Active oncologic pathology .
* Traumatic or spontaneous intra-cranial haemorrhage.
* Inability to obtain required blood samples or refusal of the informed consent necessary for it.
Prevalence of Dental Caries in a Group of Egyptian Children

Prevalence of Dental Caries in a group of Egyptian children and its relation to TV and other screens time and sugar consumption (Observational cross-sectional study)

Dental caries, are considered by the World Health Organization as a major public health problem globally, and the most widespread non-communicable disease.

Similar with other conditions that are described as non-communicable diseases (NCDs), dental caries develops as the result of a combination of genetic, physiological, environmental and behavioral factors.

The commonly accepted risk factors for dental caries include dietary habits (e.g., sugary snacks), poor oral hygiene, microbiological factors, and low socioeconomic status.

Watching TV during mealtime has a negative impact on children's dietary quality as it is associated with higher consumption of ultraprocessed foods .

It was found that having the TV on at mealtimes reduces diet quality with more high-fat, high-sugar foods and fewer fruits and vegetables and increased consumption of sugar sweetened beverages.

Overconsumption of sugar has been associated with increased risk of excessive weight gain, dental decay, poor diet quality and nutritional inadequacy in children and adolescents younger than 19 years .

Eligibility Criteria:
Inclusion Criteria:

* 1. A child with mixed dentition aged from 6-8 years old 2. Positive subject acceptance for participation in the study 3. Access to all types of screens 4. Both gender

Exclusion Criteria:

* 1. A child with a dental emergency 2. Child with a psychological problem 3. Child with chronic illness
Telemedicine and Nursing Home

Telemedicine-based care provides remote health and social care to maintain people's autonomy and increase their quality of life. The rapidly aging population has come with a significant increase in the prevalence of chronic diseases and their effects, and thus the need for increased care and welfare.

This solutions give a new opportunity for diagnosis, treatment, education, and rehabilitation, and make it possible to monitor patients with a number of chronic diseases. It also reduces socioeconomic disparity with regard to access to care and gives equal chances to patients from urban and rural areas.

This a randomized trial of telemedicine versus usual care alone to reduce hospitalization and emergency hospital admissions for Nursing Home Residents .

After an initial assessment , each participant is monitored by teleconsultation on six occasions over 12 months. Patients with usual care have an initial and a 12 months assessments.


Eligibility Criteria:
Inclusion Criteria:

* Elderly over 60 years

  * Resident in nursing homes
  * Resident with multiples chronic diseases with at least two comorbidities
  * Having given free and informed consent in writing and signed by himself and / or his legal representative

Exclusion Criteria:

* Resident unaffiliated or not beneficiary of Social Security
* Resident with a life-threatening disease
Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections

To compare the rates of clinical success of Topical Dermacyn™ vs. Oral Levofloxacin vs. Combined therapy, in subjects with mild diabetic foot infections in non-ischemic ulcers.


Eligibility Criteria:
Inclusion Criteria:

* A patient must meet all of the following inclusion criteria to be enrolled in the study:

  1. Males and females \> 18 years of age with diabetes mellitus (type 1 or type 2, controlled).
  2. Presence of infected, non-ischemic diabetic foot ulcer that involves skin and deeper soft tissue as stratified by IDSA guidelines and the UTC / 1B.
  3. Foot infections that are anticipated to be cured in 10 days of oral antibiotic therapy.
  4. Foot ulcers located in the plantar, dorsal or malleolar areas.
  5. Ulcers 1- 9 cm2 in size.
  6. An accessible infection site for culture.
  7. ABI by Doppler ≥ 0.8 or TcPO2 ≥ 30 mmHg.
  8. Palpable pulse on the study foot (either dorsalis or posterior tibial artery).
  9. Willing and able to give informed consent.
  10. Willing to comply with the requirements for participation in the study.

Exclusion Criteria:

Patients are excluded if they meet any of the following criteria at the time of randomization:

1. Previous antibiotic treatment received for more than 24 hours within 72 hours of study.
2. Necrotizing fasciitis, deep abscesses in the soft tissue, sinus tracts, gas gangrene, or infected burns.
3. Superinfected eczema or other chronic inflammatory skin conditions (i.e., atopic dermatitis).
4. The patient´s ulcer is located on the stump of an amputated extremity.
5. The patient's ulcer is due to a non-diabetic etiology.
6. Infections complicated by the presence of prosthetic materials.
7. Osteomyelitis
8. Females of childbearing potential who are unable to take adequate contraceptive precautions or are breastfeeding.
9. Known to have liver disease, with total bilirubin \> 5 times the Upper Limit of Normal (ULN); known to have neutropenia (absolute neutrophil count \<500 cells/mm3).
10. Hypersensitivity to chlorine or quinolones.
11. Need for any additional concomitant systemic antibacterial agent other than the study drug(s).
12. Concomitant glucocorticoid doses (\> 5mg prednisone a day or equivalent).
13. Adjuvant therapy with hyperbaric oxygen or topical formulations containing growth factors, antimicrobials or enzymatic debriders.
14. A history of diseases of immune function (HIV, chronic granulomatous disease).
15. Any medical condition that, in the investigator´s opinion, will require dose modification of Levofloxacin to less than 750 mg a day.
16. Has received an investigational agent ≤1 month prior to the baseline evaluation.
Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity

A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays.

An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19.

The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.


Eligibility Criteria:
CF Carrier Inclusion Criteria:

* Previously tested and shown to be a CF carrier
* English-speaking

Control Group Inclusion Criteria:

* Previously tested and shown to not be a CF carrier or CF patient
* English-speaking

Exclusion Criteria:

* Currently sick with a respiratory infection
* Prisoner Status
* Unable to provide own written, informed consent
Antibiotic Prophlaxis for High-risk Laboring Women in Low Income Countries

This study, performed over a course of 3 years in 5 collaborating hospitals in Cameroon, Africa, will randomize 750 women in labor with prolonged rupture of membranes ≥ 8 hours or prolonged labor ≥ 18 hours to identical oral regimens of 1 gram of azithromycin, 1 gram of azithromycin+2 grams of amoxicillin or placebo. Women will be followed to ascertain maternal infectious outcomes and perinatal outcomes.

This 3-arm study is a large randomized clinical trial designed to evaluate the comparative effectiveness and safety of single dose oral azithromycin or combined azithromycin+amoxicillin compared to placebo for the prevention of peripartum infections and sepsis in laboring women. We have previously shown the effectiveness of azithromycin for extended spectrum antibiotic prophylaxis in addition to the standard cephalosporin alone for reduction of post-cesarean infections. In LICs, the fraction of maternal infection and sepsis from cesarean delivery is minimal. Therefore, it is necessary to evaluate strategies aimed at reducing these morbidities in women who have vaginal births. There is an increased risk of infection in women who have prolonged labor or prolonged rupture of membranes. Drawing from our findings with azithromycin-based extended antibiotic prophylaxis for cesarean delivery, we propose to adapt the intervention and evaluate a single oral dose of azithromycin (with or without oral amoxicillin) to prevent maternal peripartum infection and sepsis. This study, performed over a course of 3 years in 5 collaborating hospitals in Cameroon, Africa, will randomize 750 women in labor with prolonged rupture of membranes ≥ 8 hours or prolonged labor ≥18 hours to 1 gram of oral azithromycin, 1 gram of azithromycin+2 grams of amoxicillin, compared to usual care (placebo). Women will be followed to ascertain maternal infectious outcomes and perinatal outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Women ≥ 37 weeks' viable singleton or twin gestation in labor planning a vaginal delivery with

  1. Prolonged membrane rupture (≥8 hours) or
  2. Prolonged labor (≥18 hours).

Exclusion Criteria:

* Clinical chorioamnionitis or any other active bacterial infection (e.g. pyelonephritis, pneumonia, abscess) at time of randomization: because standard antibiotic therapy for these conditions may confound trial intervention.
* Allergy to azithromycin or amoxicillin
* Plan for cesarean delivery prior to enrollment
* Fetal demise or major congenital anomaly: Major congenital anomalies may confound assessment of neonatal outcomes and every attempt will be made up front to exclude them from randomization. However, some unrecognized fetal anomalies may inevitably be randomized. These will not be excluded post-randomization from the primary (maternal outcome) analysis; they will be taken into consideration in the secondary analyses of neonatal outcomes.
Effect of Reiki Application on Menopausal Symptoms

In this randomized controlled study, it was aimed to determine the effect of distant reiki on menopausal symptoms. Two different hypothesis teams have been established for the study.

These; H0: There is no significant difference between the menopause rating scores of the women in the study group in which distant reiki was applied and the control group without distant reiki.

H1: There is a significant difference between the menopause rating scores of the women in the study group in which distant reiki was applied and the control group without distant reiki.

Parallel to the increase in life expectancy by years, the population of women living in the post-menopausal period is also increasing. In order to have a healthy menopause, which is an important part of women's life, it is thought that the distant reiki without health risks by women may be effective in reducing the symptoms of menopause experienced by women. In line with this information, it was aimed to determine the effect of distant reiki on menopausal symptoms. The study was carried out with menopausal women between the ages of 40-55 in Adana province in Turkey. Therefore, in the study, 48 women in the menopausal period between the ages of 40-55 was randomly assigned to reiki and control groups. Distant reiki application for 30 minutes three times a week for four weeks was applied individually to the study group. No intervention was made to the control group for a period of four weeks. The primary expected outcome of the research is the effect of distant reiki on menopausal symptoms of menopausal women. Results was applied three times in total, before the study and control application, 4 weeks and 8 weeks later.

Eligibility Criteria:
Inclusion Criteria:

* Willing to participate in research,
* Can read and write in Turkish,
* Open to communication,
* Those who are between the ages of 40-55 and do not experience menstruation for at least one year,
* Experiencing at least one or more of the menopausal symptoms,
* Not applying regular reiki,
* Those who have not surgically entered menopause,
* Women without psychiatric problems

Exclusion Criteria:

* Who do not agree to participate in the research,
* Can't read and write Turkish,
* Communication is not possible,
* Those who are younger than 40, older than 55, have experienced menstruation for at least one year,
* Do not experience the symptoms of menopause,
* Using medication for the treatment of menopausal symptoms,
* Chronic illness,
* Regular reiki is applied,
* Surgically in menopause,
* Women with psychiatric problems